Oligon Therapeutics is pioneering a novel approach to drug development through its proprietary SeekR technology platform, which integrates dual oligo-binders and dual siRNA silencers into a single self-delivering drug. This innovative design allows for systemic administration without the need for special formulations. The dual oligo-binders, which function similarly to chemical antibodies, are engineered to selectively bind to specific cell surface receptors, enhancing the precision of drug delivery. This mechanism facilitates efficient cellular internalization via receptor-mediated endocytosis, allowing the siRNA to exert its therapeutic effects by reprogramming cellular functions in targeted cell types, including T-cells and cancer cells.

The SeekR platform represents a significant technological breakthrough in RNA interference (RNAi) therapeutics, utilizing a bivalent structure that improves the efficiency of siRNA uptake by approximately tenfold. This unique design not only enhances the selectivity of the drug but also enables the targeting and destruction of various cancer cells and the reprogramming of pathogenic T-cell subtypes. Oligon Therapeutics is leveraging advancements in machine learning and AI to optimize the interactions between RNA oligo-binders and target receptors, further enhancing the potential of its therapeutic pipeline, which includes programs aimed at cancer immunotherapy and other complex diseases.

Canada

Oligon™ is an emerging biotechnology company developing a novel class of multimodal RNA therapeutics that can simultaneously silence numerous disease targets with a single RNA molecule to improve outcomes and combat emerging drug resistance. Our proprietary SeekR™ platform is used to digitally engineer and rapidly produce self-delivering therapeutics which target specific tissues with unprecedented precision and accuracy. We are focused on building a pipeline of products in oncology, yet our multimodal RNA platform can be harnessed to transform outcomes for any complex multigenic disease.

Oligon Therapeutics

Company Details